Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics (OTLK) reported financial results for Q1 FY2025 and provided key updates. The company plans to resubmit its ONS-5010 BLA in Q1 2025, with potential FDA approval expected in Q3 2025. Commercial launches of LYTENAVA™ (bevacizumab gamma) are planned for Germany and UK in Q2 2025, marking the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment in these regions.
For Q1 FY2025, OTLK reported net income of $17.4 million ($0.72 per share), compared to a net loss of $11.2 million ($0.86 per share) in the same period last year. The company had cash and cash equivalents of $5.7 million as of December 31, 2024, with additional $17.8 million received in January 2025 from warrant exercises.
In the NORSE EIGHT trial, while ONS-5010 missed the primary endpoint at week 8, it met non-inferiority margins at week 12, showing mean visual acuity improvements and similar anatomical response compared to ranibizumab.
Outlook Therapeutics (OTLK) ha riportato i risultati finanziari per il primo trimestre dell'anno fiscale 2025 e ha fornito aggiornamenti chiave. L'azienda prevede di presentare nuovamente la sua BLA per ONS-5010 nel primo trimestre del 2025, con l'approvazione della FDA attesa per il terzo trimestre del 2025. I lanci commerciali di LYTENAVA™ (bevacizumab gamma) sono previsti per Germania e Regno Unito nel secondo trimestre del 2025, segnando la prima formulazione oftalmica autorizzata di bevacizumab per il trattamento della degenerazione maculare umida in queste regioni.
Per il primo trimestre dell'anno fiscale 2025, OTLK ha riportato un reddito netto di 17,4 milioni di dollari (0,72 dollari per azione), rispetto a una perdita netta di 11,2 milioni di dollari (0,86 dollari per azione) nello stesso periodo dell'anno scorso. L'azienda aveva liquidità e equivalenti di liquidità per 5,7 milioni di dollari al 31 dicembre 2024, con ulteriori 17,8 milioni di dollari ricevuti a gennaio 2025 grazie all'esercizio di warrant.
Nell'ambito dello studio NORSE EIGHT, mentre ONS-5010 ha mancato il principale obiettivo al settimo settimana, ha soddisfatto i margini di non inferiorità alla dodicesima settimana, mostrando miglioramenti medi dell'acuità visiva e una risposta anatomica simile rispetto a ranibizumab.
Outlook Therapeutics (OTLK) informó los resultados financieros para el primer trimestre del año fiscal 2025 y proporcionó actualizaciones clave. La compañía planea volver a presentar su BLA para ONS-5010 en el primer trimestre de 2025, con la aprobación potencial de la FDA esperada para el tercer trimestre de 2025. Los lanzamientos comerciales de LYTENAVA™ (bevacizumab gamma) están planeados para Alemania y el Reino Unido en el segundo trimestre de 2025, marcando la primera formulación oftálmica autorizada de bevacizumab para el tratamiento de la DMAE húmeda en estas regiones.
Para el primer trimestre del año fiscal 2025, OTLK reportó un ingreso neto de 17.4 millones de dólares (0.72 dólares por acción), en comparación con una pérdida neta de 11.2 millones de dólares (0.86 dólares por acción) en el mismo período del año pasado. La compañía tenía efectivo y equivalentes de efectivo de 5.7 millones de dólares al 31 de diciembre de 2024, con otros 17.8 millones de dólares recibidos en enero de 2025 por la ejecución de opciones.
En el ensayo NORSE EIGHT, aunque ONS-5010 no alcanzó el objetivo primario en la semana 8, cumplió con los márgenes de no inferioridad en la semana 12, mostrando mejoras medias en la agudeza visual y una respuesta anatómica similar en comparación con ranibizumab.
Outlook Therapeutics (OTLK)는 2025 회계연도 1분기 재무 결과를 발표하고 주요 업데이트를 제공했습니다. 회사는 2025년 1분기에 ONS-5010의 BLA를 재신청할 계획이며, 2025년 3분기에 FDA 승인이 예상됩니다. LYTENAVA™ (bevacizumab gamma)의 상업적 출시가 2025년 2분기 독일 및 영국에서 계획되고 있으며, 이는 이 지역에서 습성 AMD 치료를 위한 베바시주맙의 첫 번째 허가된 안과 제형이 됩니다.
2025 회계연도 1분기 동안 OTLK는 1,740만 달러(주당 0.72달러)의 순이익을 보고했으며, 이는 작년 같은 기간의 순손실 1,120만 달러(주당 0.86달러)와 비교됩니다. 회사는 2024년 12월 31일 기준으로 570만 달러의 현금 및 현금성 자산을 보유하고 있으며, 2025년 1월에 워런트 행사로 1,780만 달러를 추가로 받았습니다.
NORSE EIGHT 시험에서 ONS-5010은 8주 차에 주요 목표를 달성하지 못했지만, 12주 차에 비열등성 기준을 충족하여 평균 시력 개선과 함께 라니비주맙과 유사한 해부학적 반응을 보였습니다.
Outlook Therapeutics (OTLK) a publié ses résultats financiers pour le premier trimestre de l'exercice fiscal 2025 et a fourni des mises à jour clés. La société prévoit de soumettre à nouveau son BLA pour ONS-5010 au premier trimestre de 2025, avec une approbation potentielle de la FDA attendue au troisième trimestre de 2025. Les lancements commerciaux de LYTENAVA™ (bevacizumab gamma) sont prévus pour l'Allemagne et le Royaume-Uni au deuxième trimestre de 2025, marquant la première formulation ophtalmique autorisée de bevacizumab pour le traitement de la DMLA humide dans ces régions.
Pour le premier trimestre de l'exercice fiscal 2025, OTLK a annoncé un revenu net de 17,4 millions de dollars (0,72 dollar par action), contre une perte nette de 11,2 millions de dollars (0,86 dollar par action) au cours de la même période l'année précédente. La société disposait de liquidités et d'équivalents de liquidités de 5,7 millions de dollars au 31 décembre 2024, avec 17,8 millions de dollars supplémentaires reçus en janvier 2025 grâce à l'exercice de bons de souscription.
Dans l'essai NORSE EIGHT, bien qu'ONS-5010 ait manqué l'objectif principal à la semaine 8, il a atteint les marges de non-infériorité à la semaine 12, montrant des améliorations moyennes de l'acuité visuelle et une réponse anatomique similaire par rapport à ranibizumab.
Outlook Therapeutics (OTLK) hat die finanziellen Ergebnisse für das erste Quartal des Geschäftsjahres 2025 veröffentlicht und wichtige Updates bereitgestellt. Das Unternehmen plant, seinen BLA für ONS-5010 im ersten Quartal 2025 erneut einzureichen, mit einer möglichen Genehmigung durch die FDA, die für das dritte Quartal 2025 erwartet wird. Die kommerziellen Markteinführungen von LYTENAVA™ (bevacizumab gamma) sind für das zweite Quartal 2025 in Deutschland und dem Vereinigten Königreich geplant, was die erste genehmigte ophthalmologische Formulierung von Bevacizumab zur Behandlung der feuchten AMD in diesen Regionen markiert.
Für das erste Quartal des Geschäftsjahres 2025 berichtete OTLK von einem Nettogewinn von 17,4 Millionen US-Dollar (0,72 US-Dollar pro Aktie), verglichen mit einem Nettoverlust von 11,2 Millionen US-Dollar (0,86 US-Dollar pro Aktie) im gleichen Zeitraum des Vorjahres. Das Unternehmen hatte zum 31. Dezember 2024 liquide Mittel und Zahlungsmitteläquivalente in Höhe von 5,7 Millionen US-Dollar, mit weiteren 17,8 Millionen US-Dollar, die im Januar 2025 durch die Ausübung von Warrants erhalten wurden.
Im NORSE EIGHT-Test verfehlte ONS-5010 zwar den primären Endpunkt in Woche 8, erfüllte jedoch die Nichtunterlegenheitsgrenzen in Woche 12 und zeigte durchschnittliche Verbesserungen der Sehschärfe sowie eine ähnliche anatomische Reaktion im Vergleich zu Ranibizumab.
- Secured Marketing Authorization for LYTENAVA in EU and UK markets
- Received $17.8 million from warrant exercise inducement in January 2025
- Reported net income of $17.4 million for Q1 FY2025
- Met non-inferiority margins at week 12 in NORSE EIGHT trial
- Missed primary endpoint at week 8 in NORSE EIGHT clinical trial
- Low cash position of $5.7 million as of December 31, 2024
Insights
The Q1 FY2025 results reveal a complex financial situation requiring careful analysis. While the reported
The company's cash position requires immediate attention. With only
The European market opportunity is substantial, with Germany alone representing over 800,000 annual bevacizumab injections. As the first approved ophthalmic formulation of bevacizumab, LYTENAVA™ could capture significant market share from current off-label use, particularly in Germany where over half of anti-VEGF injections use repackaged bevacizumab. The UK market, with 1.3 million annual injections and NICE recommendation secured, presents another major revenue opportunity.
The regulatory pathway shows promise with European approval secured and US resubmission planned for Q1 2025. The NORSE EIGHT trial results, while missing the 8-week primary endpoint, demonstrated non-inferiority at 12 weeks with clinically meaningful improvements. This data, combined with previous NORSE trials, suggests a viable path to potential FDA approval in Q3 2025.
The strategic collaboration with Cencora for global distribution infrastructure positions the company well for commercial execution, though success will depend on pricing strategy and market penetration rates in a competitive landscape dominated by established players.
- ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025
- LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025
ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update.
“With all of the recent progress made at Outlook Therapeutics and the upcoming milestones over the next few months, we expect to be a very different company by the end of 2025,” commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. “In 2025, we plan to start realizing our goal of providing patients, physicians and payers with an approved ophthalmic formulation of bevacizumab. This year, we anticipate beginning to generate the first revenue for Outlook Therapeutics with the launch of LYTENAVA™ in Germany and the UK and our BLA is on track for resubmission this quarter.”
Upcoming Anticipated Milestones
- Resubmission of the ONS-5010 BLA targeted for Q1 CY2025;
- Initial commercial launches in Germany and the UK planned to commence in Q2 CY2025; and
- Potential for US FDA approval of ONS-5010 in Q3 CY2025.
LYTENAVA™ (bevacizumab gamma) European Commercial Update
In May 2024, the European Commission granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD in the EU. Additionally, in July 2024, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the same indication in the UK. In December 2024, the National Institute for Health and Care Excellence (NICE) recommended LYTENAVA™ (bevacizumab gamma) as an option for the treatment of wet AMD. Plans for a potential 2025 launch in Germany and the UK are ongoing. Outlook Therapeutics remains confident that ONS-5010 / LYTENAVA™ is an important therapy for the treatment of wet AMD in place of off-label repackaged bevacizumab that has not received regulatory approval for use in retina diseases such as wet AMD. Outlook Therapeutics intends to launch LYTENAVA™ (bevacizumab gamma) in Germany and the UK in the second quarter of calendar year 2025.
LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and UK. Currently, over 2.5 million injections of off-label, repackaged bevacizumab are administered to patients across Europe each year, with about one third of these injections in Germany alone. In Germany, there are an estimated 1.6 million anti-VEGF retina injections each year, with over half of those injections representing use of off-label, repackaged bevacizumab. For Germany, LYTENAVA™ (bevacizumab gamma) represents an opportunity for patients there to receive an approved, cGMP produced bevacizumab for the first time. The UK market represents approximately 1.3 million anti-VEGF retina injections each year, but use of repackaged bevacizumab is not authorized. In the UK, LYTENAVA™ (bevacizumab gamma) represents the first time that most patients will have access to the therapy.
Authorization may also be sought in other European countries, Japan, and elsewhere. Outlook Therapeutics has entered into a strategic collaboration with Cencora (formerly AmerisourceBergen) to support the commercial launch of LYTENAVA™ globally following regulatory approvals. The collaborative and integrated approach is designed to support market access and efficient distribution of LYTENAVA™ to benefit all stakeholders, including retina specialists, providers and patients.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Clinical and Regulatory Update
Outlook Therapeutics believes that the complete data set for NORSE EIGHT, combined with the data from the other NORSE clinical trials, provides the required clinical evidence to support approval of the ONS-5010 BLA in the US. Outlook Therapeutics plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025. If approved by the U.S. Food and Drug Administration (FDA), Outlook Therapeutics plans to commercialize ONS-5010 / LYTENAVA™ (bevacizumab-vikg) directly in the US.
In November 2024, Outlook Therapeutics reported that in the NORSE EIGHT clinical trial, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet AMD patients, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA. NORSE EIGHT is a randomized, controlled, parallel-group, masked, non-inferiority study of approximately 400 newly diagnosed, wet AMD subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 / LYTENAVA™ or 0.5 mg ranibizumab intravitreal injections. Subjects received injections at Day 0 (randomization), Week 4, and Week 8 visits. The primary endpoint is the mean change in best corrected visual acuity (BCVA) from baseline to week 8.
In January 2025, Outlook Therapeutics announced results from the completed analysis of the 12-week safety and efficacy results for NORSE EIGHT, which indicated that ONS-5010 demonstrated clinically meaningful anatomic and functional improvements at each study timepoint. Results from the 12-week analysis demonstrated the difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity (BCVA) letters with a
Financial Highlights for the Fiscal First Quarter Ended December 31, 2024
For the fiscal first quarter ended December 31, 2024, Outlook Therapeutics reported net income attributable to common stockholders of
Adjusted net loss attributable to common stockholders for the fiscal first quarter ended December 31, 2024 includes
1 Adjusted net loss attributable to common stockholders and adjusted net loss attributable to common stockholders per share of common stock – basic and diluted are non-U.S. GAAP financial measures. See “Non-GAAP Financial Measures” below.
In January 2025, Outlook Therapeutics received
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010 / LYTENAVA™ is an ophthalmic formulation of bevacizumab for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union (EU) and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the treatment of wet AMD.
In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010 / LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010 / LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Non-GAAP Financial Measures
Outlook Therapeutics prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission (SEC). In an effort to provide investors with additional information regarding the results and to provide a meaningful period-over-period comparison of Outlook Therapeutics’ financial performance, Outlook Therapeutics sometimes uses non-U.S. GAAP financial measures (NGFM) as defined by the SEC. In this press release, Outlook Therapeutics uses “adjusted net loss attributable to common stockholders,” which is defined as net loss attributable to common stockholders excluding warrant related expenses (i.e., the excess of the fair value of the warrants upon issuance over the proceeds of the private placements that closed on March 18, 2024 and April 15, 2024) and changes in fair value of warrants and convertible promissory notes, as well as “adjusted net loss attributable to common stockholders per share of common stock – basic and diluted,” which is defined as net loss attributable to common stockholders per share of common stock – basic and diluted excluding warrant related expenses and changes in fair value of warrants and convertible promissory notes. Management uses these NGFMs because they adjust for certain non-cash items that impact financial results but not cash flows and that management believes are not related to its core business. Management uses these NGFMs to evaluate Outlook Therapeutics’ financial performance against internal budgets and targets. Management believes that these NGFMs are useful for evaluating Outlook Therapeutics’ core operating results and facilitating comparison across reporting periods. Outlook Therapeutics believes these NGFMs should be considered in addition to, and not in lieu of, GAAP financial measures. Outlook Therapeutics’ NGFMs may be different from the same NGFMs used by other companies. Reconciliations to the closest U.S. GAAP financial measures are provided in the tables below.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, the potential to resubmit the BLA for ONS-5010 and the timing thereof, expectations concerning Outlook Therapeutics’ ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including with respect to an additional clinical trial and CMC issues, expectations concerning decisions of regulatory bodies and the timing thereof, plans for commercial launch of LYTENAVA™ in Germany and the UK and the timing thereof, including the potential to launch with a partner, expected timing of revenue generation in Germany and the UK, the potential of ONS-5010 / LYTENAVA™ as a treatment for wet AMD, the market opportunity for LYTENAVA™ in Germany and the UK, plans for commercial launch of ONS-5010 / LYTENAVA™ in additional countries, expectations concerning the relationship with Cencora and the benefits and potential expansion thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, including the risk that the data from the NORSE EIGHT trial does not support the resubmission or subsequent filing by the FDA of the ONS-5010 BLA, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics’ resources, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, fluctuations in interest rates and inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
| Outlook Therapeutics, Inc. | ||||||||||
| Consolidated Statements of Operations | ||||||||||
| (Amounts in thousands, except per share data) | ||||||||||
| Three months ended December 31, | ||||||||||
| 2024 | 2023 | |||||||||
| Operating expenses: | ||||||||||
| Research and development | $ | 9,660 | $ | 4,529 | ||||||
| General and administrative | 11,947 | 5,794 | ||||||||
| Loss from operations | (21,607 | ) | (10,323 | ) | ||||||
| Loss (income) on equity method investment | 33 | (3 | ) | |||||||
| Interest income | (49 | ) | (188 | ) | ||||||
| Loss from change in fair value of promissory notes | 1,304 | 993 | ||||||||
| (Gain) loss from change in fair value of warrant liability | (40,273 | ) | 53 | |||||||
| Net income (loss) | $ | 17,378 | $ | (11,178 | ) | |||||
| Per share information: | ||||||||||
| Net income (loss) per share of common stock, basic | $ | 0.72 | $ | (0.86 | ) | |||||
| Net income (loss) per share of common stock, diluted | $ | 0.72 | $ | (0.86 | ) | |||||
| Weighted average shares outstanding, basic | 24,234 | 13,013 | ||||||||
| Weighted average shares outstanding, diluted | 24,234 | 13,013 | ||||||||
| Consolidated Balance Sheet Data | |||||||||||
| (Amounts in thousands) | |||||||||||
| December 31, 2024 | September 30, 2024 | ||||||||||
| Cash and cash equivalents | $ | 5,703 | $ | 14,928 | |||||||
| Total assets | $ | 17,006 | $ | 28,823 | |||||||
| Current liabilities | $ | 48,237 | $ | 42,554 | |||||||
| Total stockholders' deficit | $ | (50,290 | ) | $ | (73,077 | ) | |||||
| Reconciliation Between Reported Net Income (Loss) (GAAP) and Adjusted Net (Loss) (Non-GAAP), in each case | |||||||
| Attributable to Common Stockholders | |||||||
| (Amounts in thousands, except per share data) | |||||||
| Three months ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Net income (loss) attributable to common stockholders, as reported (GAAP) | $ | 17,378 | $ | (11,178 | ) | ||
| Adjustments for reconciled items: | |||||||
| Loss from change in fair value of promissory notes | 1,304 | 993 | |||||
| (Gain) loss from change in fair value of warrant liability | (40,273 | ) | 53 | ||||
| Adjusted net loss attributable to common stockholders (non-GAAP) | $ | (21,591 | ) | $ | (10,132 | ) | |
| Net income (loss) attributable to common stockholders per share of | |||||||
| common stock - basic and diluted as reported (GAAP) | $ | 0.72 | $ | (0.86 | ) | ||
| Adjustments for reconciled items: | |||||||
| Loss from change in fair value of promissory notes | 0.05 | 0.08 | |||||
| (Gain) loss from change in fair value of warrant liability | (1.66 | ) | - | ||||
| Adjusted net loss attributable to common stockholders | |||||||
| per share of common stock - basic and diluted (non-GAAP) | $ | (0.89 | ) | $ | (0.78 | ) | |
| Weighted average shares - basic | 24,233,957.00 | 13,012,833.00 | |||||
| Weighted average shares - diluted | 24,233,957.00 | 13,012,833.00 | |||||
| Weighted average shares - basic | 24,233,957 | 13,012,833 | |||||
| Add in the incremental shares for warrants | - | - | |||||
| Weighted average shares - diluted for warrants | 24,233,957 | 13,012,833 | |||||
| Weighted average shares - basic | 24,233,957 | 13,012,833 | |||||
| Add in the incremental shares for convertible debt | - | - | |||||
| Weighted average shares - diluted for convertible debt | 24,233,957 | 13,012,833 | |||||
FAQ
When will Outlook Therapeutics (OTLK) launch LYTENAVA in Germany and UK?
What were OTLK's Q1 FY2025 financial results?
When is OTLK expecting FDA approval for ONS-5010?
What were the NORSE EIGHT trial results for OTLK's ONS-5010?
How much cash does OTLK have after recent warrant exercise?
